Novaliq Gmbh

Sonja Krösser

Thomas Schlüter

Bernhard Günther

Frank Löscher

Chiara Silvana Leo

Alice Meides

Markus Beier

Hartmut Voss

Kirsten Eickhoff

Jörg Haisser

Daniela Willen

Philipp Steven

The invention provides ophthalmic compositions comprising about 0.1% (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease and provides for treatment methods thereof. The invention further provides kits comprising such compositions.

Ophthalmic composition for treatment of dry eye disease

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Opthalmic compositions comprising F6H8

The present invention provides a pharmaceutical composition comprising 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis or symptoms associated therewith. Furthermore, the present invention provides a pharmaceutical kit for the therapy of anterior or posterior blepharitis or symptoms associated therewith.

Pharmaceutical compositions for use in the therapy of blepharitis

The invention provides ophthalmic compositions comprising about 0.1 % (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.

Growing community of inventors

Heidelberg, Germany

Sonja Krösser